Thermo Fisher’s New Direct from Saliva PCR Test for COVID-19 Enables Fast, Low-Cost Results

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched a new direct from saliva PCR test for COVID-19 to enable widespread, high-frequency surveillance testing.

The Applied Biosystems TaqCheck SARS-CoV-2 Fast PCR Assay uses raw saliva samples and simplifies lab workflows using instruments that are widely available globally to deliver reliable data quickly. By performing the test directly from raw saliva and eliminating the need for equipment, materials, time and labor associated with nucleic acid extraction, the TaqCheck SARS-CoV-2 Fast PCR Assay helps labs meet the turnaround time of 24-48 hours recommended by the Centers for Disease Control and Prevention (CDC).


The TaqCheck Fast PCR Assay is ideal for institutions of higher learning with existing laboratories. Universities that do not have labs on campus can also benefit by partnering with third-party testing providers. These reference labs can leverage the assay's workflow to support significant increases in testing volume. The company has also introduced the Safe Campus Reopening Program to subsidize the cost of the test for US colleges, universities and post-secondary institutions.

"Thermo Fisher scientists are continually working to answer the call as public and private institutions take proactive measures to protect their communities," said Mark Smedley, president of Genetic Sciences for Thermo Fisher Scientific. "The TaqCheck Fast PCR Assay breaks new ground and provides global communities access to affordable surveillance testing that is easy-to-implement and delivers trusted quality and reliability so they can manage the spread of COVID-19 and return to a sense of normalcy."